However, we demonstrated that EVAML might be a key mediator of metabolic reprogramming, enhancing the mitochondrial dependence of circulating CD34+ AML cells and suggesting a more aggressive and chemoresistant phenotype. The gene discussed is CD34; the disease is acute myeloid leukemia.